Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Neurological Disease: Early-Stage R&D and Dealmaking

Published by: Decision Resources

Published: Aug. 20, 2009 - 25 Pages


Table of Contents


Executive Summary

Strategic Considerations

Stakeholder Implications

Introduction

Neurology Market: Poised for Change and Innovation

Novel Approaches to Neurological Disease Treatment

Novel Targets

Beta-Amyloid

Beta-Secretase

Tau Protein

NMDA

Nicotinic Receptors

HMG-CoA Reductase

Novel Technologies

Stem Cell Therapy

Deep-Brain Stimulation

Company Profiles

Lundbeck

CoMentis

Targacept

Vitae Pharmaceuticals

Outlook

Tables

1. Descriptions of Select Neurological Diseases

2. Top-Selling Products for the Treatment of Neurological Diseases, 2008

3. Beta-Amyloid Agents in Clinical Development for the Treatment of Neurological Diseases

4. Beta-Secretase Agents in Clinical Development for the Treatment of Neurological Diseases

5. Tau Protein Agents in Clinical Development for the Treatment of Neurological Diseases

6. NMDA Agents in Clinical Development for the Treatment of Neurological Diseases

7. Nicotinic Receptor Agents in Clinical Development for the Treatment of Neurological Diseases

8. Benefits and Drawbacks of Stem Cell Types in the Treatment of Neurological Diseases

9. Select Companies Developing Stem Cell Therapies

10. Select Deals Focusing on the Development of Neurological Disease Treatments

Figures

1. Worldwide Neurology Market Growth, 2004-2008

2. Areas of the Brain Targeted by Deep Brain Stimulation

Abstract

Introduction

How can early-stage R&D efforts be positioned to tap the remaining opportunity in the neurology drug market? Although brimming with potential, neurology drug development is also rife with unique challenges that many companies and agents have been unable to overcome, as witnessed by the failures of agents initially deemed highly promising. However, careful planning-including risk mitigation through strategic collaboration-can allow a drug developer to take advantage of the significant opportunity in this market.

Questions Answered in This Report
  • Although therapies are available for neurological disorders, most of these conditions remain undertreated, and no cures are available. What benefits do novel therapies have over existing treatment options? How can companies mitigate the risk associated with drug development?
  • Much of the innovation in drug discovery and design occurs in small companies. What companies are developing novel approaches to treat neurological diseases? What collaborations have they forged with Big Pharma?
  • The neurology market is entering a period of stagnation. What is currently driving market growth? What are the greatest needs in the treatment of neurological diseases?
Scope
  • Novel targets for neurology: Beta-amyloid, beta-secretase, tau protein, NMDA, nicotinic acetylcholinesterase receptor, HMG-CoA reductase.
  • Novel technologies for neurology: Deep-brain stimulation, stem cell therapy.
  • Focus on diseases with neuronal degradation as a primary symptom: Alzheimer's disease (AD), mild cognitive impairment (MCI), multiple sclerosis (MS), Parkinson's disease (PD), Huntington's disease (HD), ALS and other motor neuron diseases.
  • Company profiles: Lundbeck, CoMentis, Targacept, Vitae Pharmaceuticals.
  • Outlook: Challenges in drug development, recent dealmaking, need for increased research, benefits of academic collaborations.
Please note, the PDF e-mail from publisher version of this report is for a global site license.

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2012
2/15/2012 - 30